Aktuellt
SENASTE
Redeye is encouraged to learn that Initiator Pharma’s most advanced candidate, pudafensine, demonstrated statistically significant and clinically relevant efficacy in its phase IIb trial. We emphasize that the results are very positive for the company and argue that they warrant a strong positive share price reaction. We intend to raise our base case and will return with a more detailed review shortly.
LÄS MER
